Sophie Frantal
Overview
Explore the profile of Sophie Frantal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
837
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Knobl V, Maier L, Grasl S, Kratzer C, Winkler F, Eder V, et al.
J Transl Med
. 2024 Oct;
22(1):913.
PMID: 39380101
Background: Monocytes comprise subsets of classical, intermediate and non-classical monocytes with distinct anti- or pro-tumor effects in breast cancer (BC). They are modulated by estrogen, and can contribute to BC...
2.
Gnant M, Frantal S, Pfeiler G, Steger G, Egle D, Greil R, et al.
NEJM Evid
. 2024 Feb;
1(12):EVIDoa2200162.
PMID: 38319865
BACKGROUND: Adjuvant aromatase inhibitors increase osteoporosis and fractures in patients with hormone receptor–positive breast cancer. We have previously reported outcomes of the ABCSG-18 (study 18 from the Austrian Breast &...
3.
Wimmer K, Sachet M, Ramos C, Frantal S, Birnleitner H, Brostjan C, et al.
J Exp Clin Cancer Res
. 2023 Nov;
42(1):300.
PMID: 37957750
Background: Epirubicin/cyclophosphamide (EC) and docetaxel (D) are commonly used in a sequential regimen in the neoadjuvant treatment of early, high-risk or locally advanced breast cancer (BC). Novel approaches to increase...
4.
Steinmair D, Wong G, Frantal S, Rohm C, Loffler-Stastka H
World J Psychiatry
. 2022 Jan;
11(12):1328-1345.
PMID: 35070781
Background: A recent meta-analysis has confirmed that the effects of psychotherapy on patients with borderline personality disorders (BPD) are still insufficiently understood. Evidence of differences between different types of therapies...
5.
Gnant M, Dueck A, Frantal S, Martin M, Burstein H, Greil R, et al.
J Clin Oncol
. 2021 Dec;
40(3):282-293.
PMID: 34874182
Purpose: Palbociclib is a cyclin-dependent kinase 4 and 6 inhibitor approved for advanced breast cancer. In the adjuvant setting, the potential value of adding palbociclib to endocrine therapy for hormone...
6.
Zhou Q, Gampenrieder S, Frantal S, Rinnerthaler G, Singer C, Egle D, et al.
Clin Cancer Res
. 2021 Dec;
28(4):697-707.
PMID: 34862246
Purpose: Accurate response assessment during neoadjuvant systemic treatment (NST) poses a clinical challenge. Therefore, a minimally invasive assessment of tumor response based on cell-free circulating tumor DNA (ctDNA) may be...
7.
Bartsch R, Singer C, Pfeiler G, Hubalek M, Stoeger H, Pichler A, et al.
Br J Cancer
. 2021 Mar;
124(11):1795-1802.
PMID: 33762716
Background: Preoperative chemotherapy containing anthracyclines and taxanes is well established in early-stage breast cancer. Previous studies have suggested that the chemotherapy sequence may matter but definitive evidence is missing. ABCSG...
8.
Piringer G, Holzner B, Mayrbaeurl B, Heibl S, Sztankay M, Frantal S, et al.
Integr Cancer Ther
. 2020 Aug;
19:1534735420938458.
PMID: 32735463
Cancer and its treatment strategies can have adverse effects on physical functioning and quality of life. Treatment strategies for better quality of life are still an unresolved issue. Physical activity...
9.
Singer C, Pfeiler G, Hubalek M, Bartsch R, Stoger H, Pichler A, et al.
Eur J Cancer
. 2020 Apr;
132:43-52.
PMID: 32325419
Background: Immune-based strategies represent a promising approach in breast cancer (BC) treatment. The glycoprotein mucin-1 (MUC-1) is overexpressed in more than 90% of BC patients, and is targeted by the...
10.
Gnant M, Pfeiler G, Frantal S
Lancet Oncol
. 2019 May;
20(5):236.
PMID: 31044698
No abstract available.